Skip to main content
Premium Trial:

Request an Annual Quote

Spyro Mousses, John Hogenesch, Natasha Caplen, Carl Novina, Lucas Pelkmans, Nicholas Ventresca, Blaine Bowman, Upstate, Xenogen, VisEn Medical



Qiagen has created a high-throughput RNAi user forum open to all scientists, the company said this week. The forum will be coordinated by Spyro Mousses, director of cancer drug development at Translational Genomics Research Institute; John Hogenesch, professor of neurobiology at the Scripps Research Institute; Natasha Caplen of the Center for Cancer Research at NCI; Carl Novina, assistant professor of cancer immunology and AIDS at Harvard Medical School; and Lucas Pelkmans, assistant professor at the Institute for Molecular Systems Biology at the Swiss Federal Institute of Technology.

The forum will meet at twice-yearly conferences.

Charles River Laboratories this week announced it has appointed Nicholas Ventresca as corporate senior vice president of information technology and chief information officer, effective April 3.

Prior to joining Charles River Labs, Ventresca was vice president in business technology for Pfizer. He holds a BS in biology from Fordham University.

Cell Biosciences said this week that Blaine Bowman has joined the company's board as lead director.

Bowman was most recently president and CEO of Dionex, where he had been employed since 1977. He holds a BS in physics from Brigham Young University, and an MBA from Stanford University Graduate School of Business.



Upstate, a subsidiary of Serologicals, and Cisbio International this week announced the launch of HTRF KinEASE, a co-developed assay for serine/threonine kinase screening.

The new assay combines KinEASE technology, proprietary antibody and kinase substrates developed by Upstate, with Cisbio's homogenous time-resolved fluorescence technology. The overall assay is monoclonal antibody-based, and consists of three kits containing one antibody and one of three defined substrates, S1, S2, or S3. A fourth kit, HTRF KinEASE Discovery, comprises one antibody and all three peptides, the companies said.

Xenogen this week launched the IVIS Lumina Imaging System, expanding the company's current line of IVIS systems for biological imaging.

The IVIS Lumina is designed to enable researchers to visualize biological processes in living animals, non-invasively and in real time, using both fluorescent and bioluminescent imaging techniques. Xenogen said that the system was developed for principal investigators and academic institutions requiring a pre-clinical imaging system.

Xenogen also announced the opening of a Web Store, which customers can access through the company's website,

VisEn Medical this week added three optical imaging probes to its NanoSPARKS line of probes.

The three new products are AminoSPARK 680, CellSPARK 680, and AngioSPARK 680.

AminoSPARK 680 can be conjugated to a range of targeting molecules including peptides, antibodies, and small molecules, enabling custom molecular imaging in multiple disease areas, VisEn said.

CellSPARK 680 is a nanoparticle label used to track the location and movement of cells in vivo, VisEn said.

AngioSPARK 680 is a nanoparticle probe that enables fluorescent imaging of vascularity and angiogenesis, and is specifically tailored to applications in intravital microscopy, the company said.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.